

compared with a reference standard composition comprising SEQ ID NO: 1 and SEQ ID NO:2.

31. A composition according to any of Claims 1- 30 for use in therapy.

5

32. A pharmaceutical composition comprising a composition according to any of Claims 1-30 and a pharmaceutically acceptable carrier.

10

33. A composition according to any of Claims 1-30 for use in the treatment of asthma, severe eosinophilic asthma, severe asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, sub-eosinophilic asthma, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, nasal polyposis, bullous pemphigoid and eosinophilic esophagitis.

15

34. Use of the composition according to any of Claims 1-30 in the manufacture of a medicament, for the treatment of a disease selected from the group consisting of asthma, severe eosinophilic asthma, severe asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, sub-eosinophilic asthma, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, nasal polyposis, bullous pemphigoid and eosinophilic esophagitis.

20

35. The use of Claim 34, wherein the medicament is to be administered at a dose of 100 mg once every 4 weeks.